Vitamin D Supplementation in HIV Youth
| Status: | Completed |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 8 - 25 |
| Updated: | 4/17/2018 |
| Start Date: | December 2011 |
| End Date: | August 2016 |
Vitamin D Supplementation and HIV-related Complications in Children and Young Adults
The purpose of this study is to determine the correct dose of Vitamin D to give to prevent
HIV related complications.
HIV related complications.
The purpose of the this study was to compare control dose of vitamin D (low dose of 600 IU/d)
to supplementation dose (medium dose of 2000 IU/d or higher doses of vitamin D of 4000 IU/d)
on HIV-related comorbidities including immune activation, inflammation, cardiovascular
diseases, and metabolic complications in HIV-infected youth.
to supplementation dose (medium dose of 2000 IU/d or higher doses of vitamin D of 4000 IU/d)
on HIV-related comorbidities including immune activation, inflammation, cardiovascular
diseases, and metabolic complications in HIV-infected youth.
Inclusion Criteria:
- Ages 8-25
- Documented HIV-1 infection
- On stable antiretroviral therapy for > 3 months
- Cumulative antiretroviral therapy of at least 6 months
- 25(OH)D level < 30 ng/ml at screening
Exclusion Criteria:
- > 400 IU daily regular vitamin D intake
- Parathyroid/calcium disorders
- Active malignancy
- Pregnancy/intent to become pregnant/breastfeeding
- Chronic infectious/inflammatory conditions
- Creatinine clearance < 50 ml/min
- Hemoglobin < 9.0 g/dL
- Aspartate aminotransferase and alanine aminotransferase > 2.5 upper limit of normal
- Diabetes requiring hypoglycemic agents
- Known coronary artery disease
- Inability to swallow pills
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials